Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

JAK the trigger.

François-Xavier Mahon1

  • 1Laboratoire d'hématopoïèse leucémique et cible thérapeutique, Université Victor Segalen Bordeaux 2, INSERM E0217, 33076 Bordeaux Cedex, France. francois-xavier.mahon@umr5540.u-bordeaux2.fr

Oncogene
|July 12, 2005
PubMed
Summary

A specific gene mutation and a fusion protein involving JAK2 (Janus kinase 2) cause myeloproliferative disorders. This discovery highlights JAK2 as a key therapeutic target for these diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and External Validation of a Transcriptome-Based Multivariable Prediction Model for Treatment-Free Remission in Chronic Myeloid Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Chronic Myeloid Leukemia in Low- and Middle-Income Countries.

The New England journal of medicine·2026
Same author

Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.

The Lancet. Haematology·2026
Same author

Extended long-term follow-up and the survival of Stop Imatinib study.

Blood neoplasia·2026
Same author

Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMC.

Leukemia research·2025
Same author

Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial.

Leukemia·2024

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Myeloproliferative disorders are a group of diseases characterized by the overproduction of myeloid cells.
  • Genetic abnormalities play a crucial role in the development of these disorders.

Discussion:

  • Somatic mutations leading to Janus kinase 2 (JAK2) activation are recurrent in myeloproliferative disorders.
  • A PCM1-JAK2 fusion protein resulting from translocation has been identified in certain leukemias.

Key Insights:

  • Abnormal JAK2 activation is the underlying defect in a significant number of myeloproliferative disease cases.
  • These findings establish JAK2 as a critical molecular target for therapeutic intervention.

Outlook:

  • Further research into JAK2 signaling pathways may reveal novel treatment strategies.
  • Targeting JAK2 activation holds promise for managing myeloproliferative disorders.

Related Experiment Videos